SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Metrics to compare | 4592 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4592PeersSector | |
---|---|---|---|---|
P/E Ratio | −42.7x | −6.4x | −0.6x | |
PEG Ratio | 0.49 | −0.10 | 0.00 | |
Price/Book | 96.1x | 5.5x | 2.6x | |
Price / LTM Sales | - | 46.0x | 3.3x | |
Upside (Analyst Target) | −36.8% | 122.9% | 38.0% | |
Fair Value Upside | Unlock | 13.7% | 4.4% | Unlock |